We previously demonstrated that Fibroblast Growth Factor 10 (FGF10) and its receptor FGFR2b play a key role in controlling the very early stages of mammary gland development during embryogenesis [Mailleux, A.. Gli3-mediated somitic Fgf10 expression gradients are required for the induction and patterning of mammary epithelium along the embryonic axes. Development 133, 2325-35.]. However, the role of FGFR2b signaling in postnatal mammary gland development is still elusive. We show that FGF10 is expressed at high level throughout the adipose tissue in the mammary gland of young virgin female mice whereas its main receptor FGFR2 is found mostly in the epithelium. Using a rtTA transactivator/ tetracycline promoter approach allowing inducible and reversible attenuation of the FGFR2b signaling throughout the adult mouse, we are now reporting that FGFR2b signaling is also critical during postnatal mammary gland development. Ubiquitous attenuation of FGFR2b signaling in the postnatal mouse for 6 weeks starting immediately after birth is not lethal and leads to minor defects in the animal. Upon dissection of the mammary glands, a 40% reduction in size compared to the WT control is observed. Further examination shows a rudimentary mammary epithelial tree with completely absent terminal end buds (TEBs), compared to a well-branched structure observed in wild type. Transplantation of mammary gland explants into cleared fat pad of wild type mouse recipients indicates that the observed abnormal branching results from defective FGFR2b signaling in the epithelium. We also demonstrate that this rudimentary tree reforms TEBs and resumes branching upon removal of doxycycline suggesting that the regenerative capacities of the mammary epithelial progenitor cells were still functional despite long-term inactivation of the FGFR2b pathway. At the cellular level, upon FGFR2b attenuation, we show an increase in apoptosis associated with a decrease in the proliferation of the mammary luminal epithelium. We conclude that during puberty, there is a differential requirement for FGFR2b signaling in ductal vs. TEBs epithelium. FGFR2b signaling is crucial for the survival and proliferation of the mammary luminal epithelial cells, but does not affect the regenerative potential of the mammary epithelial progenitor cells. Published by Elsevier Inc.
Introduction
Mammogenesis in mouse starts approximately on embryonic day 10.5 (E10.5) with the formation of two mammary lines running in an antero-posterior direction ventrally between fore and hind limbs, one line along each flank of the embryo (Veltmaat et al., 2003 (Veltmaat et al., , 2004 . At around E11.5, lens-shaped multilayered ectodermal structures (called placodes) can be detected slightly elevated above the surrounding ectoderm presumably along each mammary line at five reproducibly precise positions. These mammary placodes subsequently transform into bulbs of epithelial cells that are morphologically distinct from the surrounding epidermis. Approximately on E15.5, each bud elongates to form a sprout, invading the fat pad precursor. Each sprout forms a lumen, which opens on the surface of the skin, where the nipple forms concurrently by epidermal invagination. At about E16, the first ramifications of the sprouts occur, and by E18.5 the sprouts have developed into small, arborized glands. After birth, the gland grows isometrically with body growth. The postnatal mammary gland is mostly composed of ducts that contain two differentiated cell types, the luminal epithelial cells, which secrete milk protein, and the myoepithelial cells, which are located at the basal surface of the luminal cells. Before the start of puberty, the MG forms a rudimentary network of ductal epithelium. At the onset of puberty, at around 3 weeks of age, under the action of circulating hormones unique structures called terminal end buds (TEBs) form at the tips of the mammary ducts (for review see Veltmaat et al., 2003) . These TEBs proliferate, ramify and actively invade the adipose tissue to allow the formation of a complex branching structure. This process takes place up to 10-12 weeks. After this developmental stage, the TEBs regress (Sternlicht et al., 2006) . Little is known about the signaling pathways controlling in vivo the proliferation of the luminal cells, which are the cells mostly involved in breast cancer (Wiseman and Werb, 2002) .
We previously reported the crucial role played by Fibroblast Growth Factor 10/Fibroblast Growth factor Receptor 2b (FGF10/FGFR2b) in the initial stages leading to the formation of the mammary placodes. The induction of most of the mammary line and four of the five mammary placodes on this line are under the control of FGF10 and FGFR2b (Mailleux et al., 2002; Veltmaat et al., 2006) . We also reported that in Fgfr2b null embryos, the remaining mammary bud (mammary bud 4) regressed due to decreased proliferation and increased apoptosis in the mammary gland epithelium (Mailleux et al., 2002) . This study therefore suggested that the FGFR2b pathway might be crucial for survival and proliferation of the mammary epithelial cells during postnatal development.
Indeed, an important role for FGFR2 signaling during postnatal mammary gland (MG) development is suggested by the fact that Fgfr2 expression is maximal in mature virgin mice, declines during pregnancy and lactation, but increases after weaning (Pedchenko and Imagawa, 2000) . The rise in Fgfr2 mRNA in the virgin animal corresponds to a significant increase in the branching of the mammary epithelial tree. During ductal development, the genes encoding the two main FGFR2b ligands, FGF10 and FGF7, are expressed at a ratio of 15 to 1 respectively (Pedchenko and Imagawa, 2000) . The expression of Fgfr2 and its associated ligands in the MG during ductal development suggests an important role for the FGFR2b pathway in post-natal growth of the mammary epithelium. Such a positive role for FGFR2b signaling in epithelial growth is re-enforced by the fact that FGF10, which mostly binds to FGFR2b, has been described as an oncogene in breast cancer cells (Theodorou et al., 2004) . In addition, FGFR2 is amplified and overexpressed in breast cancer (Grose and Dickson, 2005; Moffa and Ethier, 2007) . Mutations in FGFR2 have recently been strongly associated with a higher risk of breast cancer in postmenopausal women with no previous family history of breast cancer (Hunter et al., 2007) .
The role of FGF10/FGFR2b signaling in the epithelial/ mesenchymal interactions that characterize postnatal MG development is demonstrated through the analysis of the MG phenotype of transgenic mice allowing inducible and reversible attenuation of the FGFR2b pathway throughout the whole adult mouse upon addition of doxycycline. This study demonstrates that FGFR2b signaling in mammogenesis is not only critical during embryogenesis but also during postnatal development.
Materials and methods

Analysis of LacZ expression
Fgf10/LacZ expression was monitored in Fgf10 LacZ mice (Kelly et al., 2001) by β-galactosidase activity using whole-mount and histological revelation as described by Kelly et al. (1995) . Mammary glands (MGs) from 3-week-old virgin females were fixed 2 h in 4% PFA. Following the fixation, the MGs were washed in 1× PBS and stained in X-gal solution. A similar protocol was carried out for MG from Rosa26 mice (Zambrowicz et al., 1997 ).
Generation of rtTA; tet(O)sFgfr2b animals
CMV-Cre mice (Schwenk et al., 1995) were crossed with rtTA flox mice (Belteki et al., 2005) to generate rtTA mice expressing rtTA from the Rosa26 promoter in every single cell of the body. rtTA mice are now crossed with tet(O) soluble Fgfr2b mice (Hokuto et al., 2003) to generate double transgenic rtTA; tet (O)soluble Fgfr2b mice. These mice are on the CD1 mixed genetic background and allow inducible and reversible attenuation of the FGFR2b pathway in the embryo or mouse simply by feeding the mice with doxycycline containing food (Rodent diet with 0.0625% Doxycycline, Harlan Teklad TD01306). The reversibility of the phenotype is studied by putting the treated mice on normal food. Genotyping of each allele was done as previously described (Schwenk et al., 1995; Belteki et al., 2005; Hokuto et al., 2003) .
Antibodies
MG from 3-week-old female mice were fixed in 4% PFA overnight and stored in 70% ethanol. The tissues were embedded in paraffin and 5 μm longitudinal sections were made. IHC was performed with the Envision kit from Dako cytomation. FGFR1 antibody (Flg, 1:200, Santa Cruz Inc.) and FGFR2 (Bek, 1:200, Santa Cruz, Inc) were incubated overnight at 4°C as previously described . MG paraffin sections were treated with Cy3 conjugated-monoclonal anti α-SMA Ab (1:200, Sigma, clone 1A4) as previously described . Photomicrographs were taken using a Leica DMRA fluorescence microscope with a Hamamatsu Digital CCD Camera.
Proliferation
One of the two MGs number 4 from P35 WT and double transgenic animals (n = 3 for each) non-induced with dox (control group) were surgically removed and the operated mice were put on doxycycline food for 1 week to induce gene expression. Similar experiments were also carried out with P60 double transgenic animals (n = 3) to assess the role of FGFR2b signaling in late puberty. After a week, the animals were sacrificed and the second mammary glands 4 were removed (experimental group). The mammary glands were fixed overnight in paraformaldehyde, rinsed in PBS twice for 5 min, transferred to 70% EtOH overnight and stored in 100% EtOH. The samples were then embedded in paraffin and sections (5 μm) were cut. The PCNA staining kit (Zymed Labs Inc. 93-1143) was used for immunostaining. The total number of cells in the epithelium as well as the number of PCNA positive cells in the epithelium were scored in six photomicrographs (64× magnification), in random portions of a section of three independent mammary glands in the experimental and control group. A total number of 600 cells were counted per sample. The significance in proliferation in mammary glands between control and experimental group was evaluated by one-tailed paired t-test. P values less than 0.05 were considered to be statistically significant. To assess the effect of inactivating FGFR2b signaling on the overall ramification process, mammary glands from the control and experimental group were also stained with Carmin Red.
Analysis of cell death
Apoptotic cells on 5 μm paraffin section of P35 and P38 (days on dox) MG were detected by the incorporation of terminal deoxynucleotidyltransferase mediated dUTP nick-end labeling (TUNEL) using the "In Situ Cell Death Detection, Fluorescein" kit (Roche Applied Science) as recommended by the manufacturer. The total number of cells in the epithelium as well as the number of TUNEL positive cells in the epithelium were scored in five photomicrographs (64× magnification), in random portions of a section of three independent mammary glands in the experimental and control group. A total number of 500 cells were counted per sample.
Whole mount Carmin Red staining
The mammary gland epithelium was stained using Carmin Red as previously described (Faraldo et al., 1998) .
Quantification of the mammary gland size
Mammary glands from WT and mutant animals (treated with dox from P0 to P42, n = 3) were spread out flat on a glass slide and photographed at the same magnification (0.6×). The surface occupied by the MG (in arbitrary units) in the total field was measured using Metamorph. The significance in the size of the mammary glands between WT and mutant was evaluated by one-tailed paired t-test. P values less than 0.05 were considered to be statistically significant.
Grafting of wild type and mutant mammary gland in cleared mammary fat pad of NOD/SCI mice The mammary gland 4 from WT (n = 2) and Mutant (n = 2) at P21 were freshly dissected and individually cut in 1 mm 3 explants (8-10 pieces/MG). Explants were then transplanted into cleared mammary fat pads of NOD/SCID mice (Medina, 1996) . In these experiments, 19-day-old females were used as transplant recipients. The endogenous mammary epithelium was surgically removed from the fourth inguinal glands to provide a cleared mammary fat pad. Mutant and wild-type mammary gland explants were transplanted separately into contralateral glands of each recipient to ensure an identical host environment. 1 week after surgery, the animals were put either on doxycycline food (n = 10 animals) or normal food (n = 8 animals). The mice were sacrificed 9 weeks after surgery and the fourth inguinal mammary glands dissected. The epithelium was stained using Carmin Red as previously described (Faraldo et al., 1998) . The number of cleared fat pad filled with mammary gland epithelium was quantified.
Results
Expression of FGF10 and associated receptors FGFR1 and FGFR2 in the mammary gland of young virgin females
Immunohistochemistry in mammary glands of 3-week-old virgin females was carried out to determine the expression of FGFR1 and FGFR2. The antibodies used recognize both the "b" isoform, usually expressed in epithelia and the "c" isoform generally expressed in mesenchyme. FGF10 binds to the "b" isoform of both receptors. Fig. 1A shows that FGFR1 is detected at high level in the adipose tissue and at very low level in the epithelium. By contrast, FGFR2 is strongly detected in the ductal epithelium and expressed at lower levels in the adipose tissue. FGFR2 is also expressed in the epithelium of the terminal end buds located at the tips of the ducts in 5-week-old MG (Fig. 1C ).
The expression of Fgf10 in mammary glands of 3-week-old virgin females was also determined using Fgf10 LacZ mice Kelly et al., 2001) . Previous studies have shown that nuclear βgalactosidase expression in this mouse strain is a bona fide reporter for Fgf10 expression (Kelly et al., 2001; Mailleux et al., 2005; Sala et al., 2006; Veltmaat et al., 2006) . We found that Fgf10/β-galactosidase is expressed at high level in the adipocytes but not in the epithelium (Figs. 1D-F) confirming our previous studies showing embryonic Fgf10 expression in the fat pad (Mailleux et al., 2002) , an embryonic tissue which gives rise to the white adipose tissue.
These data therefore suggest that FGF10 produced in large amount by the adipocytes acts in a paracrine fashion on the epithelium expressing FGFR2.
Attenuation of FGFR2b during embryonic and postnatal stages demonstrate a differential requirement for FGFR2b signaling
To determine the role of FGFR2b signaling during postnatal stages, transgenic mice were generated to allow doxycyclinbased inducible and reversible attenuation of FGFR2b signaling. CMV-Cre mice, a Cre-transgenic mouse strain allowing ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells (Schwenk et al., 1995) were crossed with rtTA flox mice (Belteki et al., 2005) . After recombination of the rtTA flox allele, the transactivator rtTA is constitutively expressed from the Rosa 26 locus in every cell of the mouse including the germ cells. This constitutive rtTA mouse line was then crossed with tet(O)sFgfr2b responder line (Hokuto et al., 2003) to generate double transgenic animals allowing ubiquitous expression of soluble FGFR2b, acting as a dominant negative, from every cell of the mouse using the rtTA transactivator/ tetracycline promoter system (Gossen and Bujard, 1992) . We have validated that our double transgenic system is functional by inducing the expression of soluble FGFR2b from embryonic day 0.5 (E0.5) through E13.5. Our results indicate that double transgenic embryos exposed to doxycycline exhibit the phenotype of the previously reported Fgfr2b −/− embryos (De Moerlooze et al., 2000) . rtTA; tet(O)sFgfr2b double transgenic embryos not exposed to doxycycline as well as single transgenic embryos exposed to doxycycline were phenotypically identical to wild type embryos (data not shown). This demonstrates that there is no leakiness in the expression of soluble FGFR2b in our double transgenic embryos in absence of doxyclycline and that there is no toxic effect of doxycycline on embryonic development.
A comparison of Fig. 2A (showing a single transgenic embryo identical to wild type) with Fig. 2B indicates that double transgenic embryos exposed to doxycycline fail to form limbs and lungs (compare insets a and b). In addition, we observed a curly tail, which is a phenotype observed in Fgfr2b −/− embryos (de Moerlooze et al., 2000) but not in Fgf10 −/− embryos (Sekine et al., 1999) . These results confirm that FGFR2b signaling is crucial during organogenesis. By contrast, expression of a dominant negative FGFR2b during the postnatal period (P0 through P60) leads only to a few defects such as abnormally shaped incisors and elongated claws (Figs. 2E-H). As during embryonic stages, adult double transgenic mice not exposed to doxycycline are phenotypically equivalent to wild type mice (data not shown) indicating that there is no leakiness in the expression of soluble FGFR2b in post-natal stages. The mutant mice also appear significantly slimmer compared to wild type animals ( Fig. 2C) . Quantification of the weight shows indeed a significant reduction in mutant (n = 4) vs. wild type (n = 4) animals regardless of the gender (Fig. 2D, P b 0.03) . Upon dissection of the mammary glands (MG) from control (wild type) and double transgenic animals, we observed a 40% reduction in the total size (measured in arbitrary units) of the mutant MGs (7451 ± 881 vs. 12477 ± 1123 in mutant vs. control, P b 0.02) as well as reduced visceral fat (data not shown). Our double transgenic system relies on the proper activity of the Rosa26 promoter in different tissues allowing expression of the transactivator rtTA. As a control for these experiments, the activity of the Rosa26 promoter was determined by examining β-galactosidase activity in skin, limbs, gastrointestinal tract, heart, kidneys, lungs and MGs of adult Rosa26 mice. In all organs examined (data not shown), including the MGs (Figs. 3A-C), a robust and homogenous expression of β-galactosidase was observed. The use of the Rosa26 promoter to drive significant gene expression in major organs in adult mice was, therefore, validated.
Altogether, the data suggest that FGFR2b signaling is not essential for the function/homeostasis of organs important for sustaining the vital functions of the mice such as the lung, heart, digestive tract or kidneys. However, discrete defects unravel a function postnatally for FGFR2b in specific organs such as the incisors, the claws or the MGs. In this study, potential MG defects in rtTA; tet(O)sFgfr2b double transgenic animals were examined. To obtain consistent results, the analysis focused on MG 4 even though similar results were obtained with the other pairs of MGs (data not shown). Easy accessibility and dissection dictated the choice of this mammary gland.
Attenuation of FGFR2b signaling immediately after birth leads to absence of branching of the mammary epithelium LacZ expression in 8-week-old MG from Rosa26 mice shows that the Rosa26 promoter is active throughout the mammary epithelium both in proximal (ductal) and distal (tip) position. LacZ expression was also detected throughout the white adipose tissue, but at lower level. The expression of soluble Fgfr2b indirectly from the Rosa26 promoter is therefore likely to homogeneously affect the mammary epithelium. Carmin Red staining of wild type and double transgenic animals exposed to doxycycline postnatally for various period of time was carried out. Fig. 3 shows the degree of ramification in wild type (Figs. 3D-F) and rtTA; tet(O)sFgfr2b (Figs. 3G-I) mammary glands after 42 days of treatment with doxycycline (from P0 to P42). In the wild type MG (n = 3) a well-developed mammary tree extending beyond the lymph node used as a landmark is observed with prominent terminal end buds (TEBs). By contrast, the epithelial tree of the mutant MG (n = 5) did not reach the first lymph node but rather stayed close to the nipple region. Further examination indicated a poorly branched structure with rudimentary, thin ducts and no visible TEBs. Histological analysis revealed a simplified luminal epithelium (compare insets in Figs. 3I and F). Normal SMA expression in mutant MG indicates that the myoepithelial layer is not significantly affected (inset in Fig. 3I ).
The role of FGFR2b signaling in the mammary gland during gestation and lactation was also examined. Pregnant double transgenic (n = 2) and WT (n = 4) females (which were crossed with wild type males) were compared. Doxycycline treatment of pregnant double transgenic mice (from E7 through E14) led to a slight reduction in the formation of the alveoli compared to the WT MG ( Supplementary Fig. S2 , A-F). However, when double transgenic mice are treated during the early lactation period (from P0 through P7), no major defects can be detected compared to WT MG (Fig. S2 , G-L). Supporting the conclusion that lactation is not affected, the difference in the weight of the P7 pups in the WT and double transgenic group was not significant (6.1 g ± 0.2 g vs. 6.3 g ± 0.4 g, for pups in WT females vs. double transgenic, P = 0.14).
Thus our results indicate that FGFR2b signaling is crucial for mammary epithelial branching during early-mid puberty. It also suggests that ductal epithelium, even though affected, is less dependent on the loss of FGFR2b signaling than the epithelium in terminal end buds.
The rudimentary mammary tree resumes branching upon removal of doxycycline
Upon removal of doxycycline the rtTA/Tet(on) system allows reversibility in the expression of the gene under the control of the tetracycline promoter (Gossen and Bujard, 1992) . The study takes advantage of this feature to further evaluate the regenerative capacities of the epithelial progenitor cells in mutant mammary glands of female mice exposed to doxycycline for 42 days (from P14 to P56). In this experiment we have chosen to induce expression of doxycycline at P14 instead of P0 as we also wanted to determine also the effect of expressing soluble FGFR2b on the mammary epithelium: namely, growth arrest vs. regression of the mammary epithelial tree. As mouse mammary glands come in pairs, one of the two MG of a given pair can be ressected for evaluation without sacrificing the animal. At a later time, the second MG can be isolated and compared to the first MG from the same animal, therefore reducing sample-to-sample variability. Fig. 4 summarizes the experimental plan. In wild type mice (n = 3), the first MG at P14 and the second MG at P84 were isolated. In double transgenic mice (n = 3), treatment was started with doxycycline at P14 and the first MG was isolated at P56. MGs from P56 WT animals were also isolated independently as age-matched controls. P14 WT MGs were isolated, as this is the stage when the mutant mice were put on doxycycline. This allows determining whether the development of the rudimentary tree is simply arrested immediately at the time of doxycycline treatment or if further regression occurs. We therefore compared mutant P56 MG (Figs. 4D-F) with wild type P14 and P56 MG (Figs. 4A-C and G-I, respectively). The results indicate that, in spite of a welldeveloped white adipose tissue, the mutant mammary gland (at P56) exhibits a significant decrease in lateral ramifications compared to the control wild type MGs at P14 and P56. Interestingly, the main ducts are still maintained in the mutant MG suggesting again a differential requirement for FGFR2b signaling in the ductal vs. terminal end bud epithelium. This result suggests that attenuation of FGFR2b signaling in already formed post-natal mammary gland not only arrests the growth of the epithelial tree but also leads to its partial regression.
To determine whether the regenerative capacities of the mammary epithelial progenitors were still functional in the rudimentary epithelial tree observed in the mutant MG, the operated mutant animals (P56) were put on normal food (with no doxycycline) for 28 days (until P84). At the end of this period (P84) the second MG4 was surgically removed from wild type and mutant animals. Attenuation of FGFR2b signaling leads to a drastic decrease in the proliferation of the mammary luminal epithelium FGFR2 expression in the mammary epithelium (Fig. 1) as well as the resulting rudimentary epithelial mammary tree upon FGFR2b attenuation (Figs. 3 and 4) suggest that FGF10 acts on the epithelium to control its survival and proliferation.
To determine that this is indeed the case, one of the two MG4 in P35, mid-puberty, wild type and mutant females (n = 3) which were never fed with doxycycline was surgically removed and the operated animals were fed with doxycycline food for 1 week. The second MG4 (at P42) was then surgically removed. Therefore control and experimental mammary glands were obtained from the same animals, reducing the variability due to the mixed genetic background. Comparison of P35 (no dox, Figs. 5A-C) vs. P42 (1 week on dox, Figs. 5D-E) wild type MG indicates no changes in the appearance of the mammary epithelial tree indicating that doxycycline treatment per se does not affect MG development. In addition, mutant MG at P35 shows well-developed TEBs, a feature of WT MG, therefore supporting our previous conclusion that there is no leakage of soluble Fgfr2b expression in absence of doxycycline. By contrast, mutant MG at P42 (1 week on dox) displays a specific regression of the TEBs (Figs. 5J-L) . Our results also indicate similar expression of SMA in P35 MG compared to P42 MG (data not shown), suggesting that the myoepithelial layer is not directly affected by FGFR2b attenuation. The proliferation in the luminal epithelium of mutant MG with or without doxycycline by PCNA was then examined. A 65% decrease in proliferation in P42 (Fig. 5N) vs. P35 MG (Fig. 5M ) (16.1 ± 3.8% vs. 48.4 ± 2.1% for P42 vs. P35, respectively. P b 0.001) was observed. Similar results were obtained in late puberty (P60-P67, Fig. S1 ). An 83% decrease in proliferation in P67 (7 days on dox) vs. P60 (no dox) mutant MG (Fig. S1 ) (5.9% ± 1.6% vs. 34.0% ± 6.2% for P67 vs. P60, respectively. P b 0.001) was recorded.
Our results indicated no difference in apoptosis after 1 week treatment with doxycycline either at mid or late puberty (data not shown). However, significant apoptosis was detected in mutant MG after 3 days treatment (between P35 and P38) with doxycycline (Figs. 5O,P; 8.6 ± 2.8% vs. 2.4 ± 0.6% at P38 vs. P35, P b 0.01). Altogether our results demonstrate that FGFR2b signaling controls luminal epithelial cell proliferation as well as survival.
Branching of mutant mammary explants is severely impaired in cleared mammary fat pad of recipient mice exposed to doxycycline To confirm that the observed defects in the mutant mammary glands were directly linked to the perturbation of the FGFR2b signaling in this organ and not the result of systemic changes in hormones, transplantation of explants from wild type and mutant 3-week-old MG into 19-day-old cleared fat pads of NOD/SCID female mice was performed. Half of the recipient mice containing the mutant or wild type explants were fed with doxycycline containing food 1 week after surgery. The animals were sacrificed 9 weeks after transplantation and the development of the explants was examined. The fate of the explants into the fat pads was divided into three possible outcomes; ramified explants, explants present with no ramification and no explant visible. In the later case, the lack of visible explants in the fat pad is likely the consequence of failure to implant due to technical reasons.
For WT explants (no doxycycline, Figs. 6A,B) , a total of 8 transplanted fat pad (TFP) were considered. 87.5% of TFP show ramified explants, 0% of the TFP show explants with no ramification and 12.5% of the TFP show no explants indicating failure of the explants to engraft. Similar results were observed for WT explants exposed to doxycycline (Figs. 6C,D) . For the mutant explants without doxycycline (Figs. 6E,F) , a total of 8 TFP were considered. 75% of the TFP show ramified explants, 12.5% of the TFP show explants with no ramification and 12.5% of the TFP show no explants. This once again demonstrates that there is no leakage of soluble Fgfr2b expression in the double transgenic system. Finally, for the mutant explants on doxycycline, a total of 10 TFP were considered. 20% of the TFP show ramified explants, 60% of the TFP show explants with no ramification such as the one shown in Figs. 6G,H and 20% of the TFP show no explants. Altogether our results indicate a drastic decrease in the TFP with mutant explants showing ramification in doxycycline vs. normal food (20% vs. 75%, respectively). This outcome indicates that the effect of FGFR2b signaling on the mammary epithelium is not the consequence of alterations in the white adipose tissue and/or in levels of hormones known to control mammary branching morphogenesis such as estrogen, progesterone and prolactin.
Discussion
An inducible and reversible expression system to attenuate FGFR2b signaling in the postnatal stages
We are the first group to report the use of the rtTA/Tet(on) system to attenuate ubiquitously FGFR2b signaling in postnatal mice. In contrast to the severe phenotype observed when FGFR2b is knocked down during the embryonic stage, we could detect only minor defects when FGFR2b is inactivated in the postnatal period. These defects include defective incisors, longer claws and reduced white adipose tissue. Interestingly, the incisors unlike the molars are constantly renewed in the postnatal mouse. Indeed, it was previously suggested by Harada and colleagues that FGF10 maintains the dental epithelial stem cell compartment in the incisors, not only during the embryonic stages, but also postnatally (Harada et al., 2002; Yokohama-Tamaki et al., 2006) . Our study directly confirms the important role for FGFR2b signaling during postnatal incisor development. The longer claw phenotype observed upon attenuation of the FGFR2b pathway is more surprising as usually loss of FGFR2b signaling leads to loss of tissue. However, this phenotype is similar to the one displayed by mice where soluble FGFR2b is expressed in the hair cortex using the Foxn1 promoter (Schlake, 2005) . More work will be needed to determine the mechanisms leading to the claw phenotype. Finally, the mice under long-term treatment with doxycycline exhibit a significant decrease in the white adipose tissue, illustrated by the reduced size of the mammary gland and visceral fat in mutant animals (data not shown). Such decrease is not observed when mice are treated for a week (data not shown). Even though we cannot exclude that this reduced weight is the consequence of malnutrition due to defective incisors, it is likely that in our system, FGFR2b attenuation is also disrupting the formation of the white adipose tissue as previously reported Fig. 6 . Evidence that FGFR2b signaling in post-natal mammary gland development is epithelial cell autonomous. MG explants from WT and mutant animals were transplanted in cleared fat pad of recipient animals. Animals were fed with dox or normal food 1 week after surgery and sacrificed 9 weeks after surgery. Fat pads were stained with Carmin Red. (A,B) Recipient mouse is not exposed to doxycycline. Fat pad from with WT explant shows presence of epithelial ramification. (C,D) Recipient mouse is exposed to doxycycline. No difference with panels A,B. (E,F) Recipient mouse is not exposed to doxycycline. Fat pad from with mutant explant shows presence of epithelial ramification. (G,H) Recipient mouse is exposed to doxycycline. Fat pad with mutant explant does not ramify. Scale bar: (A, C, E, G) 1000 mm; (B, D, F, H) 400 μm. . It has been proposed that FGF10 controls adipogenesis by inducing the differentiation of the progenitors for the adipocytes (called pre-adipocytes) into adipocytes (Sakaue et al., 2002) . More recently, it has been shown that FGF10 plays also a key role in the proliferation of the pre-adipocytes (Asaki et al., 2004) . Collectively, these results indicate that long-term attenuation of FGFR2b signaling in postnatal mice leads to defects consistent with an important role of FGFR2b in survival and/or proliferation of progenitor and/or partially differentiated cells in the incisors and adipose tissue.
FGFR2b signaling plays a major role during postnatal mammary gland development
The mammary gland is mostly composed of ducts that contain two differentiated cell types, the luminal epithelial cells and the myoepithelial cells. Before the start of puberty, the MG forms a rudimentary network of ductal epithelium. At the onset of puberty, under the action of circulating hormones, terminal end buds (TEBs) form at the tips of the mammary ducts. These TEBs proliferate, ramify and actively invade the adipose tissue to allow the formation of a complex branching structure. Using an inducible and reversible FGFR2b attenuation approach, this study demonstrates a differential requirement for FGFR2b signaling in the ductal vs. terminal end bud epithelium. In particular, we show that the proliferation of the luminal epithelium is dependent upon FGFR2b signaling. Such a positive role for FGFR2b signaling in mammary epithelial growth is reinforced by the fact that FGF10 has been described as an oncogene in breast cancer cells (Theodorou et al., 2004) .
Could estrogen activity on the mammary gland epithelium be mediated by FGFR2b signaling?
During puberty, the mammary epithelial tree develops rapidly in response to changes in circulating hormones, including estrogen. The role of estrogen receptor α (Erα) in mammary gland development was previously reported by Kourach and colleagues in their genomic Erα KO mouse model (Bocchinfuso et al., 2000; Korach et al., 1996) . These mice, which turned out to be hypomorphic for Erα, displayed lack of MG development beyond the pre-pubertal stage with absence of TEBs and a rudimentary epithelial tree. However, later studies demonstrated that this phenotype could be rescued by prolactin, estradiol or progesterone demonstrating that the phenotype was due to abnormal pituitary and ovarian hormones in the mutant animals whereas Erα function was intact in the mammary gland. To address the function of estrogen signaling in the mammary epithelium, recent studies described the mammary epithelial specific inactivation of Erα (Feng et al., 2007) . The resulting mutant mammary gland displayed an arrest in MG development beyond the pre-pubertal stage with absence of TEBs. Given the phenotypic similarities between our mutant MG and the Erα MG described previously, it is obvious to speculate that estrogen signaling via Erα in the epithelium could regulate the expression of FGFR2b in this compartment. Interestingly, FGFR2 expression in the prostate epithelium, which is also under hormonal control for its postnatal development, appears to be required for androgen-mediated tissue homeostasis (Lin et al., 2007) . Therefore by keeping the level of FGFR2b expression under control, estrogen signaling would prevent mammary epithelial cells to respond excessively to the otherwise high levels of FGF10 arising from the surrounding stroma. Further studies using the available mutant mice and in vitro cell modeling will allow determining the possible relationship between FGFR2b signaling acting locally during mammary gland morphogenesis and the circulating hormones.
In conclusion, we report herein that FGFR2b signaling in mammogenesis is not only critical during embryogenesis to control the induction of the mammary placodes (for placodes 1, 2, 3 and 5), as well as to maintain the survival and proliferation of the mammary epithelial progenitor cells in placode 4 (Mailleux et al., 2002) but also during postnatal development to allow the formation and maintenance of the TEBs as well as the control of survival and proliferation of the luminal epithelial progenitor cells.
